Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of infliximab induction therapy in Crohn's disease and ulcerative colitis
2015-004618-10Phase 4Completed
- Sponsor
- Erasmus Hospital
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of infliximab in Crohn's disease and autoimmune colitis, sponsored by Erasmus Hospital. Primary endpoint: Inter-individual variability of infliximab pharmacokinetics and antibodies. Started Nov 2015; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2015-004618-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004618-10.